Rationale and design of the EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

ConclusionThe EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials will determine the effects of empagliflozin on exercise capacity and patient‐reported outcomes in patients with HFpEF and HFrEF, respectively, and provide insight into the potential of empagliflozin in the treatment of patients with HF.Clinical Trial Registration:ClinicalTrials.gov ID: NCT03448406 (EMPERIAL ‐Preserved), NCT03448419 (EMPERIAL‐Reduced).

Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: William T. Abraham, Piotr Ponikowski, Martina Brueckmann, Cordula Zeller, Hemani Macesic, Barbara Peil, Mich èle Brun, Anastasia Ustyugova, Waheed Jamal, Afshin Salsali, JoAnn Lindenfeld, Stefan D. Anker, on behalf of the EMPERIAL Investigato Tags: Study Design Source Type: research